Subscribe to Press Releases

X
Subscribe

Immunotherapies for Life

YmAbs Granted Rare Pediatric Disease Designation for hu3F8 Antibody

The FDA grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for hu3F8 for the treatment of Neuroblastoma
Read more

07-05-2017

Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer

Burtomab, a drug for metastatic neuroblastoma, has been granted Breakthrough Therapy Designation by the FDA for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis
Read more

06-07-2017

YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

Positive burtomab data presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago
Read more

06-04-2017

YmAbs Announces Acceptance of Presentations of Burtomab Data at ASCO 2017 Annual Meeting

Pivotal efficacy data for 131I-burtomab treatments of Neuroblastoma CNS Metastases and DIPG has been accepted
Read more

05-09-2017

YmAbs’ 131I-8H9 Receives EU Orphan Drug Designation

Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation
Read more

03-02-2017

YmAbs Raises $12 Million in Equity Funding

Y-mAbs Therapeutics, Inc. closes $12 million in private placement among current shareholders
Read more

01-09-2017

YmAbs to Present Company Overview at the 35th Annual J.P. Morgan Healthcare Conference 2017

Y-mAbs Therapeutics, Inc. invited to present at leading healthcare conference
Read more

01-04-2017

Priority Review Program Extended Through 2022

House of Representatives approve the 21st Century Cures Act to increase funding of the FDA and the National Institutes of Health, including a long-term reauthorization of the Priority Review Program to encourage Treatments for Rare Pediatric Diseases
Read more

12-02-2016

Y-mAbs Granted Rare Pediatric Disease Designation for Radiolabeled 124I-8H9 antibody

The U.S. Food and Drug Administration (FDA) grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for the radiolabeled antibody 124I-8H9 for the treatment of Diffuse Intrinsic Po
Read more

11-18-2016

YmAbs’ 131I-8H9 for Pediatric Patients with Neuroblastoma Leptomeningeal CNS Metastases granted Orphan Drug Designation by FDA

Y-mAbs Therapeutics, Inc. has been granted Orphan Drug Designation for its lead pediatric program 131I-8H9 for the treatment of Neuroblastoma Leptomeningeal CNS Metastases
Read more

11-16-2016

Y-mAbs Therapeutics, Inc. Enters Into Agreement For Manufacturing Of First BiSpecific Antibody Compound

Y-mAbs Therapeutics, Inc. has signed an agreement for technology transfer and scale-up process runs at Abzena
Read more

08-22-2016

Y-mAbs Therapeutics, Inc. Granted Rare Pediatric Disease Designation For Lead Compound

The U.S. Food and Drug Administration (FDA) grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for the radiolabeled antibody 131 I-8H9 for treatment of Relapsed Neuroblastoma
Read more

08-11-2016

Y-mAbs Therapeutics, Inc. Raises $15 Million In Equity Funding

Y-mAbs Therapeutics, Inc. closes $15 million expansion of its seed round
Read more

08-09-2016

MilliporeSigma to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs Therapeutics, Inc. for Lead Antibody Compound

Includes scale-up and GMP manufacturing of drugs in late-stage development. Antibody targets advanced, refractory brain tumors in pediatric patients
Read more

08-01-2016

Multimerization Platform MULTI-TAGTM presented at PEGS Boston

Novel Multimerization Platform MULTI-TAGTM for the enhancement of potency and developability of bispecific antibodies presented at Protein and Antibody Engineering Summit
Read more

04-28-2016

Y-mAbs Therapeutics, Inc. Closes $10 Million Seed Funding

Y-mAbs Therapeutics, Inc. raises $10 million in equity funding to upscale oncology focused immunotherapy venture
Read more

01-08-2016

Y-mAbs Therapeutics, Inc. Expands Management

Y-mAbs Therapeutics, Inc. hires two senior executives to strengthen medical and drug development capabilities
Read more

01-06-2016

Y-mAbs Therapeutics, Inc. Enters Into Development and Manufacturing Agreement for Antibody Compound with Patheon Biologics.

Y-mAbs Therapeutics, Inc. has signed a development and manufacturing agreement with Patheon Biologics for production of its leading monoclonal antibody, which is currently in late stage clinical development.
Read more

12-02-2015

Y-mAbs Therapeutics, Inc. Joins Forces with Cancer Center to Break New Ground on Immunotherapy

Y-mAbs Therapeutics, Inc. to collaborate with Memorial Sloan Kettering Cancer Center in New York to commercialize two clinical stage antibody programs and a protein multimerization platform, MULTI -TAG™.
Read more

10-14-2015